AACR logo

Advertisement

Table of Contents

Highlights

Highlights

Selected Articles from This Issue

Mol Cancer Ther April 1 2020 19 (4) 973-973;

MCT First Disclosures

MCT First Disclosures

Editorial Molecular Cancer Therapeutics: A Central Hub for First Disclosures in Cancer

Mol Cancer Ther April 1 2020 19 (4) 975-975; DOI:10.1158/1535-7163.MCT-20-0131
MCT First Disclosures | AuthorChoice

Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models

Anita Kulukian, Patrice Lee, Janelle Taylor, Robert Rosler, Peter de Vries, Daniel Watson, Andres Forero-Torres and Scott Peterson

Mol Cancer Ther April 1 2020 19 (4) 976-987; DOI:10.1158/1535-7163.MCT-19-0873
MCT First Disclosures

Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity

Helen Kotanides, Rose Marie Sattler, Maria B. Lebron, Carmine Carpenito, Juqun Shen, Jingxing Li, David Surguladze, Jaafar N. Haidar, Colleen Burns, Leyi Shen, Ivan Inigo, Anthony L. Pennello, Amelie Forest, Xinlei Chen, Darin Chin, Andreas Sonyi, Michael Topper, Lauren Boucher, Prachi Sharma, Yiwei Zhang, Douglas Burtrum, Ruslan D. Novosiadly, Dale L. Ludwig, Gregory D. Plowman and Michael Kalos

Mol Cancer Ther April 1 2020 19 (4) 988-998; DOI:10.1158/1535-7163.MCT-19-0893

Review

Review

A Historic Perspective and Overview of H-Ras Structure, Oncogenicity, and Targeting

Lihua Shu, Dongsheng Wang, Nabil F. Saba and Zhuo G. Chen

Mol Cancer Ther April 1 2020 19 (4) 999-1007; DOI:10.1158/1535-7163.MCT-19-0660

Small Molecule Therapeutics

Small Molecule Therapeutics

Aurora B Kinase Promotes CHIP-Dependent Degradation of HIF1α in Prostate Cancer Cells

Kuntal Biswas, Sukumar Sarkar, Neveen Said, David L. Brautigan and James M. Larner

Mol Cancer Ther April 1 2020 19 (4) 1008-1017; DOI:10.1158/1535-7163.MCT-19-0777
Small Molecule Therapeutics

Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance

Marco H. Hofmann, Rajeswaran Mani, Harald Engelhardt, Maria A. Impagnatiello, Sebastian Carotta, Marc Kerenyi, Seila Lorenzo-Herrero, Jark Böttcher, Dirk Scharn, Heribert Arnhof, Andreas Zoephel, Renate Schnitzer, Thomas Gerstberger, Michael P. Sanderson, Girish Rajgolikar, Swagata Goswami, Sumithira Vasu, Peter Ettmayer, Segundo Gonzalez, Mark Pearson, Darryl B. McConnell, Norbert Kraut, Natarajan Muthusamy and Jürgen Moll

Mol Cancer Ther April 1 2020 19 (4) 1018-1030; DOI:10.1158/1535-7163.MCT-19-0789
Small Molecule Therapeutics

Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071

Sophie Piperno-Neumann, James Larkin, Richard D. Carvajal, Jason J. Luke, Gary K. Schwartz, F. Stephen Hodi, Marie-Paule Sablin, Alexander N. Shoushtari, Sebastian Szpakowski, Niladri Roy Chowdhury, A. Rose Brannon, Thiruvamoor Ramkumar, Leanne de Koning, Adnan Derti, Caroline Emery, Padmaja Yerramilli-Rao and Ellen Kapiteijn

Mol Cancer Ther April 1 2020 19 (4) 1031-1039; DOI:10.1158/1535-7163.MCT-19-0098

Large Molecule Therapeutics

Large Molecule Therapeutics

Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity

Sun K. Ho, Zhenghai Xu, Archana Thakur, Melvin Fox, Siu Sze Tan, Enrico DiGiammarino, Li Zhou, Mien Sho, Belinda Cairns, Vivian Zhao, Mengli Xiong, Josue Samayoa, Charles M. Forsyth, David B. Powers, Debra T. Chao, Diane Hollenbaugh, Hamsell M. Alvarez and Yoshiko Akamatsu

Mol Cancer Ther April 1 2020 19 (4) 1040-1051; DOI:10.1158/1535-7163.MCT-19-0608
Large Molecule Therapeutics | AuthorChoice

Effect of Modulating FcRn Binding on Direct and Pretargeted Tumor Uptake of Full-length Antibodies

Lidia Nazarova, Hanine Rafidi, Danielle Mandikian, Gregory Z. Ferl, James T. Koerber, Christopher W. Davies, Sheila Ulufatu, Jason Ho, Jeffrey Lau, Shang-Fan Yu, James Ernst, Jack D. Sadowsky and C. Andrew Boswell

Mol Cancer Ther April 1 2020 19 (4) 1052-1058; DOI:10.1158/1535-7163.MCT-19-1015
Large Molecule Therapeutics | AuthorChoice

Antitumor Activity of the IGF-1/IGF-2–Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models

Ulrike Weyer-Czernilofsky, Marco H. Hofmann, Katrin Friedbichler, Rosa Baumgartinger, Paul J. Adam, Flavio Solca, Norbert Kraut, Holly M. Nguyen, Eva Corey, Gang Liu, Cynthia C. Sprenger, Stephen R. Plymate and Thomas Bogenrieder

Mol Cancer Ther April 1 2020 19 (4) 1059-1069; DOI:10.1158/1535-7163.MCT-19-0378

Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers

Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers

Oxaliplatin–DNA Adducts as Predictive Biomarkers of FOLFOX Response in Colorectal Cancer: A Potential Treatment Optimization Strategy

Maike Zimmermann, Tao Li, Thomas J. Semrad, Chun-Yi Wu, Aiming Yu, George Cimino, Michael Malfatti, Kurt Haack, Kenneth W. Turteltaub, Chong-xian Pan, May Cho, Edward J. Kim and Paul T. Henderson

Mol Cancer Ther April 1 2020 19 (4) 1070-1079; DOI:10.1158/1535-7163.MCT-19-0133

Models and Technologies

Models and Technologies

High-Throughput Generation of Bispecific Binding Proteins by Sortase A–Mediated Coupling for Direct Functional Screening in Cell Culture

Fabio Andres, Martin Schwill, Ykelien L. Boersma and Andreas Plückthun

Mol Cancer Ther April 1 2020 19 (4) 1080-1088; DOI:10.1158/1535-7163.MCT-19-0633